- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3 - Pairing Patients with the Right Therapies
In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.
In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.
Dr Shafer-Weaver explains that with CTLA-4, melanoma responds well to immunotherapy, but there is work being done currently regarding PD-1 and PD-L1. Results show that even though PD-L1 negative tumor respond well, patients highly express PD-L1 respond better.
“I think the biggest thing right now is there is no consistency in the field, and so I think it is kind of hard right now at this stage to get a grasp on that because we do not have standardized assays that all labs do the same,” she said. “It is not a common thing; specialized labs do that.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy
December 16th 2025The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.
Read More
